Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
52 studies found for:    Open Studies | "Salivary Gland Diseases"
Show Display Options
Rank Status Study
1 Recruiting BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
Conditions: HIV;   Salivary Gland Disease;   Benign Lymphoepithelial Lesion
Interventions: Drug: Ciprofloxacin;   Drug: Placebo
2 Not yet recruiting Characterization of Diseases With Salivary Gland Involvement
Conditions: Healthy Volunteer;   Sjorgren's Syndrome;   Salivary Gland Disease
Intervention:
3 Recruiting Salivary Evaluation in Normal Volunteers
Conditions: Healthy;   Salivary Gland Disease
Intervention:
4 Recruiting A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
Conditions: Nasopharyngeal Neoplasms;   Salivary Gland Diseases;   Bone Marrow Diseases;   Mucositis
Interventions: Drug: Amifostine every-other-day regimen;   Drug: Amifostine everyday regimen
5 Recruiting Salivary Biomarkers for Sjögren's Syndrome Detection
Condition: Sjögren's Syndrome
Intervention:
6 Unknown  A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Malignant Salivary Gland Tumors
Interventions: Drug: Cisplatin: 40 mg/m2 weekly during radiation;   Radiation: Radiation: 60-66 Gy in 2 Gy daily fractions
7 Recruiting Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Conditions: Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
Intervention:
8 Recruiting A Study of Flt3-Ligand Levels in Sjögrens Syndrome
Condition: Sjogrens Syndrome
Intervention:
9 Unknown  Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Conditions: Xerostomia;   Depression;   Hypertension
Interventions: Drug: Malic Acid;   Other: Placebo
10 Recruiting Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
Condition: Xerostomia
Interventions: Other: LactoXeros;   Device: Aequasyal
11 Recruiting Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease
Conditions: Primary Sjogren Syndrome;   Secondary Sjogren Syndrome;   Aqueous Deficient Dry Eye Disease;   Evaporative Dry Eye Disease
Interventions: Drug: Restasis;   Drug: Refresh Endura
12 Unknown  Hyperbaric Oxygen for the Treatment of a Dry Mouth Which Occurred After Radiotherapy
Condition: Radiation-Induced Xerostomia
Intervention: Drug: oxygen
13 Recruiting Evaluation of Salivary Gland Dysfunction
Conditions: Sjogren's Syndrome;   Xerostomia
Intervention:
14 Recruiting Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Laryngeal Verrucous Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Biological: Cetuximab;   Biological: Recombinant Interleukin-12;   Other: Laboratory Biomarker Analysis
15 Recruiting Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
Conditions: KERATOCONJUNCTIVITIS SICCA;   XEROSTOMIA;   SICCA SYNDROME;   PRIMARY SJOGREN SYNDROME
Interventions: Device: Laser 3R 790nm infrared Ga AIAs;   Device: Laser 3R 790 nm infrared  GaAIAs
16 Recruiting Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
Conditions: Human Papillomavirus Infection;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma
Interventions: Drug: Veliparib;   Other: Placebo;   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Radiation Therapy;   Drug: Hydroxyurea;   Drug: Paclitaxel;   Drug: Carboplatin
17 Not yet recruiting A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Biological: AMG 557/MEDI5872;   Biological: Placebo
18 Recruiting Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Conditions: Recurrent Salivary Gland Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Intervention: Drug: eribulin mesylate
19 Unknown  Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
Conditions: Sjogren's Syndrome;   Mesenchymal Stem Cells
Intervention: Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)
20 Unknown  Rebamipide for the Treatment of Xerostomia in sjögren Syndrome
Condition: Improving Symptoms of Dry Mouth in Sjőgren's Syndrome
Intervention: Drug: Rebamipide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years